Catalog Products » IL-18BP[Biotin], His & Avi, Human
Manual
Manual
COAs

IL-18BP[Biotin], His & Avi, Human

Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice.
$660.00
Z04504-100

Ask us a question
Product Introduction
Species Human
Protein Construction
IL-18BP (Thr31-Gly194)
Accession # O95998-2		 His Avi
N-term C-term
Conjugate Biotin
Purity > 95% as determined by Bis-­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity IL-18BP[Biotin], His & Avi, Human on CM5 Chip via anti­his antibody can bind Human IL­-18，No Tag in SPR assay (Biacore T200). Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 20.5 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 52-65 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.
Back

IL-18BP[Biotin], His & Avi, Human

IL-18BP[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »

IL-18BP[Biotin], His & Avi, Human

IL-18BP[Biotin], His & Avi, Human, His Tag captured on CM5 Chip via anti-his antibody can bind Human IL-18, No Tag with an affinity constant of 0.90 nM as determined in SPR assay (Biacore T200). »

<
>

Background
Target Background Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer,components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice.
Synonyms IL-18BP; Igifbp; IL-18BPA
Back

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.